Owkin partners with Stanford Medicine on lung cancer and mesothelioma treatment research using AI
Using Stanford Medicine’s multimodal patient data, including molecular data, the research aims to discover new biomarkers to improve the development of new treatments. It also aims to further the understanding of treatment-resistance mechanisms and identify potential treatment targets. Owkin, who is sponsoring the research, is contributing its expertise in AI to the study.
The research is led by principal investigator Olivier Gevaert, PhD, Associate Professor of Medicine at the Stanford School of Medicine.
Dinesh Divakaran, VP of Partnerships, North America at Owkin, said:
The convergence of cutting-edge AI and high-quality patient data is fuelling a revolution in cancer research. We are excited to work with Stanford Medicine to further our mission of using AI to find the right treatment for every patient.
By combining our expertise in AI with Stanford Medicine’s high-quality multimodal patient data, we hope to better understand the treatment of lung cancer and mesothelioma and make a lasting difference to the lives of patients worldwide.
About Owkin
Owkin is building the first universal AI co-pilot called K to lay the foundation for Biological Artificial Superintelligence (BASI). This co-pilot integrates a suite of AI agents that decode complex biology, accelerate research, and dramatically increase productivity. Acting as copilots, Owkin K agents will automate drug discovery and diagnostics and power next-generation pharma companies.
Owkin K will be powered by the world’s largest federated multimodal patient data network, a robotized lab, leading AGI technologies, and cutting-edge multimodal foundation models and LLMs.
